4.7 Article

Identification of predominant GNPTAB gene mutations in Eastern Chinese patients with mucolipidosis II/III and a prenatal diagnosis of mucolipidosis II

期刊

ACTA PHARMACOLOGICA SINICA
卷 40, 期 2, 页码 279-287

出版社

ACTA PHARMACOLOGICA SINICA
DOI: 10.1038/s41401-018-0023-9

关键词

mucolipidosis; lysosomal enzymes; genotype; GNPTAB; GNPTG; gene mutation; phenotype; prenatal diagnosis

资金

  1. Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20152520]
  2. Shanghai Science and Technology Committee [16JC1404600]
  3. National Natural Science Foundation of China [81570516, 81270936]
  4. National Key Research and Development Program [2016YFC0905100, 2016YFC0901505]

向作者/读者索取更多资源

Mucolipidosis II alpha/beta, mucolipidosis III alpha/beta, and mucolipidosis III. are autosomal recessive disorders belonging to the family of lysosomal storage disorders caused by deficiency of the UDP-N-acetylglucosamine, a lysosomal enzyme N-acetylglucosamine-1-phosphotransferase (GlcNAc-phosphotransferase) localized in the Golgi apparatus, which is essential for normal processing and packaging of soluble lysosomal enzymes with initiating the first step of tagging lysosomal enzymes with mannose-6-phosphate (M6P). Mucolipidosis II and III are caused by mutations in the GNPTAB and GNPTG genes, and patients with these diseases are characterized by short stature, skeletal abnormalities, and developmental delay. In this study we report 38 patients with mucolipidosis II and III enrolled in Eastern China during the past 8 years. The diagnosis was made based on clinical characteristics and measurement of plasma lysosomal enzyme activity. Sanger sequencing of GNPTAB and/or GNPTG for all patients and real-time quantitative PCR were performed to confirm the diagnosis. In addition, 11 cases of prenatal mucolipidosis II were diagnosed based on measurement of the enzyme activity in amniotic fluid supernatant and genetic testing of cultured amniotic cells. Based on molecular genetic tests, 30 patients were diagnosed with mucolipidosis II alpha/beta, 6 were diagnosed with III alpha/beta and 2 were diagnosed with III.. Thirty-seven different GNPTAB gene mutations were identified in 29 patients with mucolipidosis II alpha/beta and six patients with III alpha/beta. These mutations included 22 new mutations (p.W44X, p.E279X, p.W416X, p.W463X, p.Q802X, p.Q882X, p.A34P, p. R334P, p.D408N, p.D534N, p.Y997C, p.D1018V, p.L1025S, p.L1033P, c.88_89delAC, c.890_891insT, c.1150_1151insTTA, c.1523delG, c.2473_2474insA, c.2980_2983delGCCT, c.3094delA, and deletion of exon 9). Four new GNPTG gene mutations were identified (c.13delC, p.Y81X, p.G126R and c.609+1delG) in two mucolipidosis III. patients. Among the 11 cases of prenatal diagnosis, four were mucolipidosis II fetuses, three were heterozygous, and the remaining four were normal fetuses. This study expands the mutation spectrum of the GNPTAB and GNPTG genes and contributes to specific knowledge of mucolipidosis II/III in a population from Eastern China.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据